Clinical screening protocols for fatty liver disease may be inadvertently overlooking the patients who would benefit most from early intervention. The widely adopted diagnostic pathway combining FIB-4 index scores with elastography imaging appears to have significant blind spots in identifying metabolic dysfunction-associated steatotic liver disease (MASLD) cases prime for treatment. This diagnostic gap represents a critical challenge in liver health management, as MASLD affects an estimated 30% of adults globally and can progress to cirrhosis without proper detection and care. The FIB-4 index, which calculates liver fibrosis risk using age, liver enzymes, and platelet counts, has become a cornerstone of MASLD screening due to its simplicity and cost-effectiveness. When combined with vibration-controlled transient elastography, this sequential approach was designed to efficiently identify patients requiring immediate attention while avoiding unnecessary procedures for low-risk individuals. However, emerging evidence suggests this streamlined protocol may create a paradoxical situation where patients in earlier disease stages—who typically respond better to lifestyle interventions and emerging pharmacological treatments—slip through the diagnostic net. This represents a fundamental tension in liver disease screening between efficiency and sensitivity. Early-stage MASLD patients often lack the advanced fibrosis markers that trigger positive FIB-4 scores, yet these individuals may derive the greatest benefit from weight management, dietary modifications, and newer medications like GLP-1 receptor agonists. The clinical implications extend beyond individual patient outcomes to population health strategy, as missed early diagnoses could result in more patients progressing to advanced liver disease, ultimately increasing healthcare costs and reducing treatment effectiveness across the healthcare system.